Related Experiment Videos
Acitretin monotherapy in acrodermatitis continua Hallopeau
R J van Dooren-Greebe1, P C van de Kerkhof, A Chang
1Department of Dermatology, University of Nijmegen, The Netherlands.
Acta Dermato-Venereologica
|January 1, 1989
Summary
Acitretin monotherapy effectively treated acrodermatitis continua Hallopeau, clearing pustulation. This treatment also significantly inhibited leukotriene B4-induced polymorphonuclear leukocyte accumulation in the skin.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Acrodermatitis continua Hallopeau (ACH) is a rare, chronic inflammatory skin disease characterized by sterile pustules.
- Current treatment options for ACH can be limited, necessitating exploration of alternative therapies.
Observation:
- A single patient with ACH was treated with acitretin (Ro 10-1670) as monotherapy.
- The patient received a daily dosage of 45 mg of acitretin.
Findings:
- Acitretin monotherapy led to complete resolution of pustulation in the ACH patient.
- At the effective dosage, acitretin markedly inhibited the intraepidermal accumulation of polymorphonuclear leukocytes induced by leukotriene B4.
Implications:
- Acitretin demonstrates therapeutic potential as a monotherapy for acrodermatitis continua Hallopeau.
- The inhibitory effect on leukotriene B4-induced neutrophil migration suggests a potential mechanism of action for acitretin in inflammatory dermatoses.